Immediate blood mediated immune response in immunocompromised recipients to islet infusion in vitro

Recruiting

• Conditions: Diabetes sugar; 10018424; 10003816; 10014705

• Registration Number: NL-OMON44045
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Group 1: healthy volunteers, i.e. >18 years old and no current medication use except for over the counter drugs
Group 2: patients who are at least 3 months after transplantation
Group 3: patients with type 1 diabetes, matched for duration of diabetes with the patients in group 2

Exclusion Criteria

Unable to give consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Incremental increase of cytokines (i.e. TNF-alpha) in plasma after whole blood<br /><br>exposure to allogeneic islets</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Incremental increase of complement membrane attack complex (C5b-9) in plasma<br /><br>after whole blood exposure to allogeneic islets<br /><br>Incremental increase of islet associated blood markers (Micro-RNA*s, PPP1R1A)<br /><br>in plasma after whole blood exposure to allogeneic islets<br /><br>Incremental increase of cytokines (i.e. IL-1A and IL1B) in plasma after whole<br /><br>blood exposure to allogeneic islets</p><br>